Covalent organic frameworks (COFs) usually crystallize as insoluble powders and their processing for suitable devices has been thought to be limited. Here, it is demonstrated that COFs can be mechanically pressed into shaped objects having anisotropic ordering with preferred orientation between the hk0 and 00/ crystallographic planes. Pellets prepared from bulk COF powders impregnated with LiClO.sub.4 displayed room temperature conductivity up to 0.26 mS cm.sup.−1 and stability up to 10.0 V (vs. Li.sup.+/Li.sup.0). This outcome portends use of COFs as solid-state electrolytes in batteries.

Covalent organic frameworks (COFs) usually crystallize as insoluble powders and their processing for suitable devices has been thought to be limited. Here, it is demonstrated that COFs can be mechanically pressed into shaped objects having anisotropic ordering with preferred orientation between the hk0 and 00/ crystallographic planes. Pellets prepared from bulk COF powders impregnated with LiClO.sub.4 displayed room temperature conductivity up to 0.26 mS cm.sup.−1 and stability up to 10.0 V (vs. Li.sup.+/Li.sup.0). This outcome portends use of COFs as solid-state electrolytes in batteries.

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: ##STR00001##
where A1, A2, G, R1, R2, R3, R4, and W are described herein.

Reagents and methods for labeling biomolecules with astatine isotopes in higher oxidation states. The reagents and methods allow for efficient labeling of biomolecules, such as antibodies, without the formation of high molecular weight by products that arise due to .sup.211At-promoted dimerization and higher aggregation of the conjugated biomolecules, and diminish cellular retention of astatine caused by cellular oxidization of the bonded astatine atom in vivo.

Reagents and methods for labeling biomolecules with astatine isotopes in higher oxidation states. The reagents and methods allow for efficient labeling of biomolecules, such as antibodies, without the formation of high molecular weight by products that arise due to .sup.211At-promoted dimerization and higher aggregation of the conjugated biomolecules, and diminish cellular retention of astatine caused by cellular oxidization of the bonded astatine atom in vivo.

An organic compound is represented by formula (1). In the formula (1), R.sub.1 to R.sub.24 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryloxy group, a silyl group, and a cyano group. ##STR00001##

An organic compound is represented by formula (1). In the formula (1), R.sub.1 to R.sub.24 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryloxy group, a silyl group, and a cyano group. ##STR00001##

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

Described herein is the preparation of a 1,3,5-triazinyl benzimidazole and chemical intermediates used in the synthetic process.